Cargando…
Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives
Major breakthroughs have been achieved in the management of metastatic pancreatic ductal adenocarcinoma (PDAC) with FOLFIRINOX (5-fluorouracil + irinotecan + oxaliplatin) and gemcitabine plus nab-paclitaxel approved as a first-line therapy, although the prognosis is still poor. At progression, patie...
Autores principales: | Lellouche, Lisa, Palmieri, Lola-Jade, Dermine, Solène, Brezault, Catherine, Chaussade, Stanislas, Coriat, Romain |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264726/ https://www.ncbi.nlm.nih.gov/pubmed/34285720 http://dx.doi.org/10.1177/17588359211018539 |
Ejemplares similares
-
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020) -
Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)
por: Morikawa, Kei, et al.
Publicado: (2020) -
EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer
por: Crees, Zachary D, et al.
Publicado: (2020) -
Bayesian network meta-analysis of efficacy and safety of neoadjuvant therapy for non-small-cell lung cancer
por: Ren, Yijiu, et al.
Publicado: (2020) -
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
por: Frost, Nikolaj, et al.
Publicado: (2021)